Cassava Sciences Inc (SAVA)
25.92
-0.29
(-1.11%)
USD |
NASDAQ |
Nov 04, 13:00
Cassava Sciences Revenue (Quarterly)
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2013 | 35.24M |
September 30, 2013 | 1.958M |
June 30, 2013 | 1.959M |
March 31, 2013 | 1.958M |
December 31, 2012 | 2.468M |
September 30, 2012 | 2.725M |
June 30, 2012 | 2.724M |
March 31, 2012 | 2.973M |
December 31, 2011 | 2.747M |
September 30, 2011 | 2.749M |
June 30, 2011 | 2.752M |
March 31, 2011 | 3.236M |
December 31, 2010 | 8.009M |
September 30, 2010 | 2.895M |
June 30, 2010 | 2.656M |
March 31, 2010 | 3.249M |
December 31, 2009 | 3.729M |
September 30, 2009 | 3.763M |
June 30, 2009 | 6.236M |
March 31, 2009 | 6.835M |
December 31, 2008 | 8.244M |
September 30, 2008 | 30.29M |
June 30, 2008 | 10.55M |
March 31, 2008 | 14.64M |
December 31, 2007 | 14.06M |
Date | Value |
---|---|
September 30, 2007 | 15.81M |
June 30, 2007 | 14.06M |
March 31, 2007 | 22.05M |
December 31, 2006 | 6.336M |
September 30, 2006 | 18.51M |
June 30, 2006 | 13.75M |
March 31, 2006 | 15.33M |
December 31, 2005 | |
September 30, 2005 | |
June 30, 2005 | |
March 31, 2005 | |
December 31, 2004 | |
September 30, 2004 | |
June 30, 2004 | |
March 31, 2004 | |
December 31, 2003 | |
September 30, 2003 | |
June 30, 2003 | |
March 31, 2003 | |
December 31, 2002 | |
September 30, 2002 | |
June 30, 2002 | |
March 31, 2002 | |
December 31, 2001 | |
September 30, 2001 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (Quarterly) Benchmarks
Bristol-Myers Squibb Co | 11.89B |
Eli Lilly and Co | 11.44B |
Seelos Therapeutics Inc | -- |
Biomarin Pharmaceutical Inc | 745.74M |
EyePoint Pharmaceuticals Inc | 9.477M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 6.155M |
Total Expenses (Quarterly) | 61.40M |
EPS Diluted (Quarterly) | 0.13 |
Enterprise Value | 1.050B |
Earnings Yield | -5.44% |
Operating Earnings Yield | 2.77% |
Normalized Earnings Yield | 18.36 |